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Detection of circulating immune complexes in patients with gb-
merulonephritis. A panel of three immune complex (IC) assays was
used in this study to test sera from patients with glomeruloneph-
ntis (GN): the Raji cell radioimmune assay (IRCA), the radio-
labeled Clq binding assay (IC1qBA), and the microcomplement
consumption test (MCT). The sensitivity and specificity of each
assay was evaluated in preliminary studies, and the greater sensitiv-
ity (5 to lOig of aggregated human 'y-globulin [AHG] per ml of
serum) and IgG specificity of the IRCA was apparent. Problems
related to the preliminary heat inactivation of test sera, the inter-
action of CIq with substances other than IC, and the effects of
suboptimal storage of test sera were experienced with the MCT
and, to a lesser extent, the ICIqBA. The individual reactivities of
the different assays were exploited by using them in combination.
Thus ICs were detected by one or more of the assays in 87% of
patients with systemic lupus erythematosus (SLE), 65% of patients
with GN associated with other systemic diseases, and 39% of
patients with primary GN. ICs were detected more frequently in
patients with acute GN than chronic ON, and in patients with low
serum C3, C4, and properdin factor B (C3PA) levels.
Detection des immuns-complexes circulants chez les malades at-
teints de glomérulonéphrite. Un éventail de trois types de détermi-
nation des complexes immuns a été utilisé dans ce travail, pour Ic
serum de malades atteints de glomérulonéphrite: le dosage radio-
immunologique utilisant les cellules Raji (IRCA), Ic dosage
par radiocompétition de C1Q (ICIqBA) et le microtest de con-
sommation du complement (MCI). La sensibilité et Ia spécificité
de chaque dosage ont été Cvaluées dans des etudes préliminaires et
Ia plus grande sensibilité (5 a 10 ig de 'y-globulines humaines
agrégées (AHO) par ml de serum) et Ia spCcificité d'IgG de IRCA
sont apparues. Les problèmes lies a l'inactivation préalable par la
chaleur des serums, l'interaction de Clq avec des substances autres
que IC et les effets de Ia conservation des serums, ont Cté évalués
avec MCI et, dans une moindre mesure, avec ICIqBA. Les réac-
tivitCs individuelles des diffCrents dosages ont été exploitées en les
associant, Ainsi les IC ont été détectées par un test ou plus chez
87% des malades atteints de lupus érythémateux disséminé (SLE),
chez 65% des malades atteints de ON associée a d'autres maladies
systémiques et 39% des malades atteints de ON pnimaire. Les IC
ont été détectés plus souvent chez les malades atteints de GN aigue
que de ON chronique, et plus souvent chez les malades ayant des
concentrations sériques faibles de C3, C4, et C3PA.
The role of circulating immune complexes (IC) in
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the pathogenesis of glomerulonephritis (GN) in man
is based on analogies with animal models of immune
complex-mediated glomerulonephritis (ICGN) [I].
Characteristic granular deposits of immunoglobulin
(Ig) and complement (C) consistent with IC deposits
are detected in the glomeruli of over 70% of patients
with GN [2]. Some of these patients have depressed
serum C levels [3], C breakdown products in the
circulation [4], and cryoglobulins [5, 6], or rheuma-
toid factor [7], which also suggest the presence of IC.
Final confirmation of the concept and diagnosis of
ICON requires the detection of IC in the serum of
such patients and the identification of antigen in the
circulating IC and in the glomerular deposits. The
recent development of sensitive methods for the de-
tection of IC should help to further define the immu-
nopathogenesis of GN and could supplement renal
immunofluorescence (IF) studies by providing the
physician with a convenient serologic measurement
in diagnosis and management.
The technology is still new, and although many
different IC assay systems have been proposed, it is
clear that none are infallible and that each has its own
special reactivity, sensitivity, and idiosyncrasies. As-
says which are based on the physicochemical proper-
ties of IC include analytical or sucrose gradient ultra-
centrifugation [8, 9], precipitation with polyethylene
glycol [10], and the detection of cryoglobulins [11].
Assays based on the immunochemical properties of
IC are, in general, more sensitive. These rely on the
altered reactivity of the Fc fragment of the corn-
plexed Ig heavy chain which causes fixation of C
[12, 13], binding of Clq [14—17], and binding of rheu-
matoid factor (RF) [181; or on the special properties
of IC-bound C components, which cause binding to
bovine conglutinin [19], and the production of serum
immunoconglutinins [20]. Finally, there are assays
based on the cellular reactivities of IC: IC-induced
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platelet aggregation [21], phagocytosis of IC by pen-
toneal macrophage cells [22], inhibition of C-de-
pendent lymphocyte EAC rosette formation [23], and
binding of IC to the C receptors of certain lympho-
blastoid cell lines [24].
In this study, we chose to employ a panel of three
different IC assays to test sera from patients with
GN. These are the Raji cell radioimmune assay [24],
in which the binding of serum IC to cell surface C
receptors is quantitated; the radiolabeled Clq bind-
ing assay [15], which quantitates the binding of Clq
to serum IC; and the microcomplement consumption
test [12, 13], which measures serum anti-comple-
mentary activity by quantitating consumption of
added C by the test serum. In this way, the individ-
ual reactivities of different assays could be evaluated
and exploited. Sera from patients with a spectrum of
renal diseases were tested, and the results correlated
with clinicopathologic information, Renal IF detec-
tion of granular deposits of Ig and C was used as the
criterion for ICGN.
Methods
ICassays
The Raji cell radioimmune assay (JR CA) [241. Raji
cells, a lymphoblastoid cell line derived from Bur-
kitt's lymphoma, were cultured in Eagles minimal
essential medium (MEM) and were used in the assay
when a concentration of 1 X 106 cells per ml was
reached. Cell viability, as determined by trypan blue
exclusion, was greater than 95%. Each test was per-
formed in triplicate. Raji cells (2 X 106) in 200d of
1% bovine serum albumin-MEM (BSA-MEM) were
reacted with 25l of a 1:4 dilution of test serum for
45 mm at 37°C. The cells were washed three times
with 1% BSA-MEM and then reacted with approxi-
mately 2.5tg of goat antihuman IgG labeled with
iodine 125 ('251-goat antihuman IgG) in 3Otl of 1%
BSA containing '311-BSA for 30 mm at 4°C. The cells
were washed once in 1% BSA-MEM, and radioac-
tivity in the cell pellet was determined in a gamma-
counter. The uptake of '251-goat antihuman IgG was
calculated after correcting for nonspecific binding of
'311-BSA and the result referred to a standard curve of
the uptake of antibody by cells incubated with aggre-
gated human gamma globulin (AHG) in normal hu-
man serum (NHS). The amount of complexes in the
test serum was expressed as tg of AHG equivalent
(equiv) per ml of serum.
The radiolabeled Clq-binding assay (JCIqBA). The
assay was modified from Nydegger et al [15]. Clq was
isolated from fresh NHS by using the method of
Yonemasu and Stroud [25], except that relative salt
concentrations of 0.04M and 0.078M were used for
the first and second precipitation steps, respectively.
The purity of the isolate was confirmed by immuno-
electrophoresis using rabbit antisera to whole human
serum and to human Clq. The Clq was stored at
—70°C in aliquots at a concentration of 1 mg per ml.
500-cg quantities were radiolabeled with 0.5 to 1.0
mCi of 1251 using chloramine T [261, and specific
activities of 0.3 to l.4Ci per g were obtained. 1%
BSA was added, and aliquots were stored at —70°C.
For use in the assay, an aliquot was thawed, diluted
in isotonic Veronal-buffered saline (VBS) [27] con-
taining 1% BSA, and centrifuged at 10,000 >< g for 30
mm at 4°C. The upper one half of the supernatant
was used for the assay. Each test was performed in
duplicate. 200l of serum in lOOtl of VBS was heated
at 56°C for 30 mm, cooled to 25°C, and approxi-
mately 0.ltg of '251-Clq in a l°°-Ml volume was
added. After 30 mm at 25°C, 2.5 ml of polyethylene
glycol (PEG) (Union Carbide; mol wt, 6,000) in 0.1M
borate buffer (pH, 8.4) was added to a final concen-
tration of 2.6% and reacted for 30 mm at 25°C. The
precipitate, obtained after centrifugation at 1000 X g
for 30 mm, was washed once with 2.6% PEG and then
counted in a gamma-counter. The result was ex-
pressed as percent binding of added '251-Clq.
The microcomplement consumption test (MCT). A
modification of the assays described by Mayer et al
[12] and by Mowbray et al [13] for the detection of
anticomplementary activity in sera was employed.
Each test was performed in duplicate using glass
tubes. A lOO-il test serum was heated at 56°C for 30
mm and then cooled for 15 mm at 0°C. Fresh NHS
diluted to contain 2 to 2.5 C H50 units was added in
300d of VBS and reacted for 30 mm at 37°C. Two
hundred microliters of a 3% suspension of sheep red
blood cells, optimally sensitized with rabbit antisheep
red cell 1gM antibody, was added and incubated for
60 mm at 37°C. The mixture was then diluted with
1.0 ml of ice-cold VBS, centrifuged at 1500 X g for 10
mm, and cell lysis quantitated by measuring the re-
leased hemoglobin (412 nM) using a spectrophotome-
ter (Gilford). Background absorption with the test
serum blank (100l of serum and 1.5 ml of VBS)was
subtracted and the result expressed as percent inhibi-
tion of control lysis with C alone (100 tl of VBS
replacing the test serum).
A panel of 66 control sera was obtained from
healthy laboratory personnel and stored in aliquots
at —70°C. Sera from the panel were used to deter-
mine the 95% confidence limit for normal serum in
each of the assays. This was 11.0% binding of Clq in
the IC1qBA and 30% inhibition of control lysis in the
MCT. The background binding in the IRCA, how-
ever, varied considerably from day to day, and in
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order to control this variation, four standard control
sera, selected to statistically represent the distribution
of the total control group, were tested in each day's
assay. The binding obtained with these sera was used
to determine the upper limit of normal for each day,
and quantitation of the test sera was expressed as (N)
ig of AHG equivalents per ml above this value, using
the formula
N = X — (e + 2.2627 \/SE2 + SE2),
where X = absolute value of test serum in tg of AHG
per ml, e = mean control value in tg of AHG per ml,
SE = standard error of control group, sn = stan-
dard error for the variance in triplicate determina-
tions of the test serum, and 2.2627 = t at P = 0.05 for
nine degrees of freedom used in analysis. Using this
system, the mean (±sE) tg of AHG per ml values
obtained on six different days with nine test sera were
360 33, 243 20,50 + 6,66 6, 102 12,26 6,
84 10, 56 8, and 50 6. (e values ranged from
8.4 to 39.6 .tg AHG per ml.)
In vitro evaluation of IC assays
Detection ofAHG and the effect of heat inactivation
of serum. The sensitivity of the assays was assessed by
determining the minimum amount of AHG detected
in NHS. AHG was prepared from Cohn Fraction II
by using the method described by Mauer et al [28],
which employs an ultracentrifugation step to remove
unaggregated gamma globulin. Sucrose density
gradient fractionation of '251-labeled AHG showed
the aggregates to be 40 to 100 5. Protein concentra-
tion was quantitated by micro-Kjeldahl nitrogen de-
termination, and the AHG was stored in aliquots at
—70°C. Prior to use in the assays, each aliquot was
centrifuged at 10,000 X g for 5 mm. Serial dilutions
of AHG were incubated in NHS for 30 mm and then
tested in the assays.
The effect of heat inactivation (56°C for 30 mm) of
sera was evaluated using NI-IS, NHS with added
AHG, and selected test sera.
Detection of in vitro-formed complexes. Complexes
of varying antigen-antibody ratios were formed in
Vitro with human serum albumin (HSA) and rabbit
anti-HSA antibody, BSA and rabbit anti-BSA anti-
body, and with tetanus toxoid (Wyeth) and tetanus
immune human serum. Tubes were incubated for 60
mm at 37°C and then for 18 hr at 4°C. Precipitates
obtained by centrifugation at 2000 X g were washed
with 0.l5M phosphate buffered saline (PBS) (pH, 7.2),
and the protein content (micro-Kjeldahl nitrogen de-
termination) was used to define the equivalence
point. The supernatants were then tested in the IC
assays.
Detection of IC in experimental sera. Sera from
normal rabbits and from rabbits with BSA-induced
acute and chronic serum sickness [29] were obtained
and tested.
The effects of storage and handling conditions of
sera. A panel of sera was tested in the assays after
repeated freeze-thawing or after storage at 25°, 4°,
—20°, or —70°C.
The influence of non-IC reactants. The effects of
heparin, deoxyribonucleic acid (DNA), and endo-
toxin were studied by testing NHS to which hep-
arm (Lipo-Hepin, Riker Laboratories), DNA (calf
thymus DNA, Worthington Biochemical Corp.), or
E. co/i endotoxin (Difco Laboratories) had been
added. The influence of serum antilymphocyte anti-
bodies on the IRCA was studied by a Raji-cytotox-
icity assay. A modification of the microcytotoxicity
assay, described by Terasaki and McClelland [30],
was employed. One microliter of test serum which
had been heat inactivated at 56°C for 30 mm was
added to a microdroplet of 1,000 Raji cells under
mineral oil and reacted for 30 mm at 25°C. Two
microliters of rabbit C was added and incubated
for three hours at 25°C. The percent of cytotoxicity
was determined by eosin dye exclusion under phase
contrast microscopy. Thirty-three samples of sera
from patients with systemic lupus erythematosus
(SLE) were tested, and the results were correlated
with those of the IRCA.
Sucrose density gradient fractionation of test sera.
Three hundred microliters of 1:2 dilutions of selected
test sera were applied to 5 ml of 10 to 37% sucrose
gradients in PBS with a 200-al 60% sucrose "cush-
ion." 7S ('311-IgG) and 19S (1251-IgM) markers were
applied to identical gradients. The gradients were
centrifuged at 250,000 X g for 6.2 h in an SW 50.1
rotor, and 30 drop fractions were collected. Each
fraction was then dialyzed against PBS for 48 hr and
tested in the IRCA. The IgG concentration of each
fraction was quantitated by radioimmunoassay for
human IgG.
Patients and sera
Sera from two groups of patients were studied
separately.
A retrospective study of stored sera. Sera from 213
patients who were referred by contributors for IF
evaluation of renal disease were selected for study.
Selection was based upon renal IF findings, so that
only patients with unequivocally positive or negative
IF findings were included. Patients were then sub-
categorized according to available clinical and patho-
logic information. No protocol was followed for the
collection and handling of the sera in this group, all
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of which had been thawed and refrozen at least once
before IC determination. The IRCA was used in this
group because preliminary studies indicated that this
assay is least affected by serum handling and storage
conditions.
A prospective study. Samples of sera were obtained
from 85 consecutive patients with GN presenting to
UCLA Harbor General Hospital. In each patient
appropriate investigations were performed to estab-
lish a definitive clinical or pathologic diagnosis.
Renal biopsies were performed in 69 patients with
light microscopic and IF findings. Serum C3, C4, and
properdin factor B (C3PA) determinations [31] were
carried out in all patients, and when indicated, sera
were tested for C3 nephritic factor activity [32], anti-
nuclear antibody, and antiglomerular basement
membrane (anti-GBM) antibodies [33]. Sera for IC
determinations were obtained as follows: blood sam-
ples were collected in glass vacutainer tubes, allowed
to clot at 25°C for 60 mm, and the serum separated
by centrifugation at 2000 rpm for 10 mm at 25°C.
The serum was stored in 0.5 ml aliquots at —70°C
until being tested in the IRCA, the ICIqBA, and the
MCT. Samples of control sera from 31 healthy labo-
ratory personnel were collected and tested in the
same way.
Results
In vitro evaluation of IC assays
Detection of aggregated human gamma globulin
(A HG) and the effect of heat inactivation of serum. All
three assays were able to detectS to l0.tg of AHG per
ml of normal human serum (NHS), which is in ac-
cord with sensitivities previously reported with these
assays [15, 24, 34]. In the ICIqBA and the MCT,
however, this sensitivity was only obtained if AHG
was added to pre-heat inactivated NHS. When AHG
was added to fresh NHS and then heat inactivated,
which more closely resembles the situation in vivo,
the minimum amount of AHG detectable by the
IC1qBA or the MCT was 50 to 100 g per ml. These
findings suggest that heat inactivation is not very
effective in removing bound C, and that this factor
may limit the detection of in vivo-formed IC by these
assays. On the other hand, there was no evidence for
heat-induced aggregation of serum gamma globulin
(the background '251—Clq binding was slightly less
with heat inactivated NHS than with fresh NHS), or
for thermolabile IC (known positive sera remained
positive in the IRCA after heat inactivation). Finally,
there was an upper limit of AHG concentration be-
yond which the assays plateau and preclude absolute
AHG quantitation. This limit was approximately
1,0o°g per ml in the IRCA, 700kg in the ICIqBA,
and 200tg in the MCT.
Detection of in vitro formed IC. All three assays
were able to detect IC formed in vitro in moderate
antigen excess. The assays were less sensitive with low
mol wt complexes formed in extreme antigen excess.
Figure 1 shows the detection of HSA-anti-HSA com-
plexes with the IC1qBA.
Detection of IC in experimental sera. Sera from
rabbits with BSA-induced serum sickness and pro-
teinuric ICGN were strongly positive in the ICIqBA
but negative in the MCT. The binding of rabbit
serum anti-BSA antibody to cell surface BSA (de-
rived from the fetal calf serum culture medium) pre-
cluded the use of the IRCA in these sera.
The effects of storage and handling conditions of
sera. The effects of repeated (10 X) freeze-thawing of
test sera and of standing at 25°C for four hours were
evaluated. Under these conditions, NHS became
anticomplementary in the MCT, but no effect was
noted in either the IC1qBA or the IRCA. The anti-
complementary activity was primarily a storage-in-
duced phenomenon; all of 12 NHSs became anti-
complementary after two days at 25°C, seven of 12
became anticomplementary after three days at 4°C,
and five of 12 after three days, at —20°C. Similar
findings by Nielsen and Svehag [35] were attributed
to aggregation of serum y-globulin. The effect was
not enhanced by repeated freeze-thawing cycles and
was not observed in NHS stored at —70°C for up to
21 days. Optimal handling of test sera and —70°C
storage are thus particularly critical in the MCT.
The influence of non-IC reactants (Table 1). Hepa-
rin, when added to NHS, produced anti-comple-
mentary activity in the MCT and increased binding
of '251-Clq in the ICIqBA. In the IC1qBA (Fig. 2),
the effect was maximal with 100 U of heparin per
ml of NHS but was still detected with less than 1 U
per ml. Heparin had no effect on the IRCA. Sim-
ilarly, DNA, both native and denatured, caused an
increase in '251-Clq-binding when added to NHS.
The effect, however, was less marked than that of
heparin; maximum specific '251-Clq-binding was
2.7% with 50kg of DNA per ml. DNA was anti-
complementary in the MCT but had no effect on the
IRCA. E. coli endotoxin (100ig per ml of NHS) had
no significant effect on either the IC1qBA or the
IRCA, but was anticomplementary in the MCT. Fi-
nally, nine of 33 samples of sera from patients with
SLE (27%) were found to have cytotoxic activity (>
10% cells killed) when tested with Raji cells in the
microcytotoxicity assay. Eight of these nine samples
of sera (89%) were positive in the IRCA (mean, 150tg
of AHG equiv per ml), compared with 19 of 24 (79%)
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and I 23tg of AHG per ml, respectively, for the cyto-
toxic negative group. Analysis of the individual sera
showed some correlation between cytotoxic activity
and the degree of IRCA positivity. Although not
conclusive, these findings suggest that serum-
lymphocyte antibodies may contribute to IRCA posi-
tivity.
Sucrose density gradient fractionation of test sera
(Fig. 3). NHS, serum from a patient with acute GN
and glomerular IC deposits, and serum from a pa-
tient with SLE were fractionated by sucrose density
gradient ultracentrifugation, and the fractions were
tested in the IRCA. Thirteen to nineteen S peaks of
IRCA binding were detected in the two nephritic
sera, presumably representing the IC containing frac-
tions, but the majority of the IRCA binding in the
SLE serum was in fact associated with the 7S frac-
tion. After correction for IgG content, the binding
observed with the SLE 7S fraction was 2.3 times
greater than with the NHS 7S fraction. This mono-
meric reactant in SLE serum may represent anti-
lymphocyte antibody or antibodies that bind to cell
Serum
anti- Sub-
lympho- optimal
Test Heparin DNA Endotoxin
cyte
antibody
storage
conditions
MCT ++ ++ ++ 0 ++
ICIqBA ++ + 0 0 0
IRCA 0 0 0 ? 0
1 10 100 1,000
Heparin, units/mi of NHS
Fig. 2. The effect of heparin (added to normal human serum [NHSJ in
Vitro) on the radiolabeled Clq-binding assay.
components, but is not yet fully characterized (R. A.
Eisenberg, personal communication).
Results of IC study
Retrospective study of stored sera with the IRCA
(Tables 2 and 3). Of the 213 patients, there were 41
with SLE, 111 with non-lupus GN and granular gb-
merular deposits of Ig and C, 31 with IF-negative
renal diseases, 7 with antiglomerular basement mem-
brane (anti-GBM) antibody disease, and 23 renal
transplant patients (Table 2). Sera samples in the IF-
negative renal disease group (end-stage GN, hyper-
tensive renal disease, chronic pyelonephritis, etc.)
were used as an internal control for this study, since
these sera had been handled and stored in the same
manner as the entire group. It was recognized, how-
ever, that circulating IC may still be present in pa-
tients with end-stage ON in whom glomerular IC can
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Fig. 1. Detection of in vitro-formed human serum albumin (HSA)-
anti-HSA complexes by the radiolabeled Clq-binding assay.
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Table 1. Influence of non-immune complex reactants on the Raji
cell radioimmune assay (IRCA), the radiolabeled Clq-binding
assay (ICIqBA), and the microcomplement consumption test
(MCT)
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(—); and systemic lupus erythematosus, by the broken line
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Table 2. Retrospective study of stored sera for circulating
immune complexes (IC)
IRCA
Positive/total
studied %
SLE
IF-positive renal disease
IF-negative renal disease
Anti-GBM antibody disease
Transplant sera
28/41
25/Ill
3/31
0/7
6/23
68
23
10
0
26
a Abbreviations used are: IRCA, the Raji cell radioimmune assay;
SLE, systemic lypus erythematosus; IF, immunofluorescence;
anti-GBM, antiglomerular basement membrane.
no longer be detected. Three of these control sera
(10%) were positive. In contrast, 68% of the SLE sera,
23% of the non-SLE IF-positive GN sera, and 26% of
the renal transplant sera were positive. None of the
anti-GBM antibody disease sera was positive. The
results indicate that the prevalence of IRCA positiv-
ity is much greater in SLE than in any other group.
The prevalence in both the non-SLE IF-positive GN
group and in the transplant group, however, was
greater than in the control group.
Of the 38 patients in the non-SLE IF-positive GN
group with definitive histologic diagnoses (Table 3),
the IRCA was most often positive in acute GN
(AGN) (five out of seven). In particular, none of the
12 patients with rapidly progressive GN (RPON),
none of the five with membranoproliferative ON
(MPGN), and only one of the five with membranous
GN (MGN) were positive. It must be emphasized
that the groups are really too small for meaningful
interpretation; and in another study, for example, we
found that six of ten patients with RPGN were posi-
tive in the IRCA (Tung et al, submitted for pub-
lication). Patients with kidney transplants were sub-
categorized by IF evaluation of the grafted kidneys
into those with granular deposits of IG and C (sug-
gesting glomerular IC deposits) and those with IF-
negative grafts (Table 3). Six of the 14 patients with
IF-positive grafts were positive in the IRCA, and
three of these six patients had clinical and pathologic
evidence suggesting recurrence of their original ON
in the transplant kidney. None of the nine patients
with IF-negative kidney grafts was positive in the
IRCA.
Prospective study of GN sera with the IRCA, the
ICIqBA, and the MCT(Tables 4 and 5). The patients
were categorized into three major groups: SLE (N =
23), ON associated with other systemic diseases (N =
17), and primary ICON, i.e., ON with granular de-
posits of Ig and C in the absence of systemic disease
(N = 36). The prevalence of positivity of sera in these
groups and in the control group (N = 31) is given for
each assay, and for the panel of assays (Table 4).
Each group of test sera had a higher prevalence of
positivity with each test than did the control group.
This was more marked, however, in the SLE group
(particularly with the IRCA, 74%), and in the group
with ON associated with other systemic diseases (par-
ticularly with the IC1qBA, 41%), than in the primary
ON group. The amounts of IC detected in patients
with primary ON were also less than in SLE or ON
associated with other systemic diseases (Fig. 4). The
correlation between the three assays was not statisti-
cally significant, and when the three assays were used
in combination, the prevalence of positivity in each of
the three patient categories was further increased, i.e.,
SLE, 87%; ON with other systemic disease, 65%;
primary ON, 39%; (control, 10%).
Patients were subcategorized according to clinico-
pathologic criteria. Data from patients with primary
ON, ON associated with non-SLE systemic diseases,
and from nine additional patients (anti-OBM anti-
body disease [N = 3], minimal lesion nephrotic syn-
drome [N = 5], preeclamptic toxemia [N = 1]) is
given in Table 5. Once again, the numbers in each
group are small. Thus, in the primary ON group,
four of seven patients with AGN, three of eight with
mesangial injury ON, and four of eleven with MPON
were positive in one or more of the assays. In the
group with systemic diseases, four of six patients with
subacute bacterial endocarditis (SBE), three of four
with polyarteritis nodosa (PAN), and two patients
with membranous glomerulonephritis (MON) and
Sjögren's syndrome were positive. None of the three
patients with antiglomerular basement membrane
(anti-GBM) antibody disease was positive. Serum
Table 3. Subclassification of patients in study cf stored sera for
circulating immune complexes (IC)
Raji cell radioimmune assay
positive/iota/studied
IF-positive renal disease with histologic diagnosis
AGN 5/7
Focal GN 2/5
RPGN 0/12
MPGN 0/5
MGN 1/5
FSGN 0/I
CGN 1/3
Transplant sera
IF-positive graft 6/14
IF-negative graft 0/9
a Abbreviations used are: AGN, acute glomeruloriephritis; RPGN,
rapidly progressive GN; MPGN, membranoproliferative GN;
MGN, membranous GN; FSGN, focal sclerosing GN; CGN,
chronic ON; IF, immunofluorescence.
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Table 4. Prospective study of glomerulonephritis (ON) sera for
circulating immune complexes (lC)
Patients
IRCA IClq BA MCT
percent positive
Any test
SLE (N = 23) 74 35 27 87
OthersystemicGN 29 41 18 65
(N= 17)
PrimaryGN(N=36) 14 17 14 39
Control(N=31) 3 3 6 10
Abbreviations used are: IRCA, the Raji cell radioimmune assay;
ICIqBA, the radiolabeled Clq-binding assay; MCT, the micro-
complement consumption test, SLE, systemic lupus erythemato-
sus. N denotes the number of patients studied.
anticomplementary activity was detected in three of
the five patients with minimal lesion nephrotic syn-
drome, a condition not thought to be mediated by
circulating IC, but in which positive results have been
reported with the macrophage uptake assay [36], the
Clq deviation test [37], and the lymphocyte EAC
rosette test [38]. These sera were negative in the
IRCA and the IC1qBA. Anticomplementary activity
was detected in the one patient with pre-eclamptic
toxemia (PET) in this study, a condition in which
glomerular immune deposits have been reported [39],
and in nine of nine women in the third trimester of
pregnancy (W. A. Border, unpublished observa-
tions). Again, these sera were negative in the IRCA
and the ICIqBA. Thomson et al [40] reported serum
anticomplementary activity in 5 of 14 patients with
PET, but found no other corroborative evidence for
circulating IC.
Complement (C) data on the sera from the three
groups of patients in the prospective study is given in
Table 6. Overall, there is an inverse correlation be-
tween C levels (C3, C4, C3PA) and positivity in the
assays. This correlation was more marked with the
IRCA and the MCT than with the ICIqBA. C3 neph-
ritic factor was detected in two patients with MPGN;
one was positive in the MCT only, and the other was
negative in all three assays.
Serial IC determinations by the IRCA and the
ICIqBA were performed with 55 samples of sera
from seven patients in the prospective study: three
with SLE, two with Henoch-Schönlein purpura
(HSP), one with MPGN, and one with mesangial IgA
disease. Of the three SLE patients, one was repeat-
edly negative in the IRCA, one was repeatedly posi-
tive, and one was converted from positive to negative.
Serial IRCA determinations in the patients with
HSP, MPGN, and IgA disease were consistently
negative. There was considerably more variation us-
ing the ICIqBA. Thus, sera from the three patients
with SLE and from the patient with IgA disease were
positive on some occasions and negative on others.
Sera from the patients with HSP and MPGN were
consistently negative in the IC1qBA.
Discussion
The sensitivity of IC assays has generally been
evaluated by the in vitro detection of aggregated hu-
man gamma globulin (AHG). Extrapolation from
sensitivities reported in the literature are limited by
the fact that no two batches of AHG are identical,
and estimation of sensitivity will be lower with prepa-
rations that have not been freed of monomeric
gamma globulin than with totally aggregated prepa-
rations. Finally, the sensitivity should refer to the
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Fig. 4. Quantitation of circulating immune complexes in prospective study of glomerulonephritis
sera with the radiolabeled Clq-binding assay (ICIqBA), theRaji cell radioimmune assay (IRCA),
and the microcomplement consumption test (MCT). The shaded area indicates 95% confidence
limit for each assay. The control group is denoted by the open circles (0); systemic lupus
erythematosus, by the closed circles (•); other systemic glomerulonephritic diseases, by the
open triangle (A); and primary glomerulonephritis, by the closed triangle (A).
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Table 5. Subclassification of patients in prospective study of
glomerulonephritis (ON) sera for circulating immune complexes(1C)
IRCA ICIqBA MCT
CIin.-path. subcategory number positive
Any test
Primary ON
AGN(N=7) I
Mesangial injury GN 1(N=8)
RPGN(N=2) 0
MPGN(N=ll) 3
MGN(N=2) 0
FSGN(N=4) 0
CGN(N=2) 0
2
2
0
0
0
2
0
1
2
1
1
0
0
0
4
3
1
4
0
2
0
ON associated with systemic disease
SBE(N=6) 2
PAN(N=4) 1
HSP(N=2) 0
HUS(N=2) 0
Vasculitis (N = I) 0
Sjägren's disease 2(N=2)
3
2
0
I
0
I
1
0
0
I
0
1
4
3
0
2
0
2
Other ON
Anti-GBM antibody 0
disease (N = 3)
Minimal lesion 0
(N=5)
PET(N=l) 0
0
0
0
0
3
1
0
3
1
a Abbreviations used are: IRCA, the Raji cell radioimmune assay;
lClqBA, the radiolabeled Clq-binding assay; MCI, the micro-
complement consumption test; SBE, subacute bacterial endo-
carditis; PAN, polyarteritis nodosa; HSP, Henoch-Schönlein
purpura; HUS, hemolytic-uremic syndrome; PET, preeclamptic
toxemia. See Table 3 for other abbreviations. N denotes the
number of patients studied.
detection of AHG in serum rather than buffer. In this
study, the Raji cell radioimmune assay (IRCA) was
more sensitive (5 to 10tg of AHG per ml serum) than
the radiolabeled Clq-binding assay (IC1qBA) and the
microcomplement consumption test (MCT) (50 to
100tg of AHG per ml). Studies with in vitro-formed
IC showed that the assays can readily detect large
complexes formed in moderate antigen excess but
that they are less sensitive with small complexes
formed in extreme antigen excess.
The sensitivity of the IC1qBA and the MCT with
AHG added to fresh serum and subsequently heat
inactivated was less than with AHG added to pre-
heat inactivated serum. This reduced sensitivity is
probably due to inhibition by pre-fixed C, which
implies that the ability of these assays to detect IC
which have fixed C in vivo might be impaired relative
to detection with the IRCA. The heat inactivation
step has been previously criticized [41]. On one hand,
heat-induced aggregation of serum -y-globulin could
produce false positive results, and on the other hand,
false negatives might be obtained with thermolabile
IC reactants. In this study, we found no evidence for
heat-induced aggregation; in fact, the background
binding of Clq in the ICIqBA was slightly less with
heat inactivated sera than with fresh serum. (This
observation was also made by Zubler et al [42] and
has been attributed to the incorporation of Clq into
the Clqrs complex in fresh but not in heated serum.)
Similarly, heat inactivation of test sera did not affect
IRCA positivity. Heat-labile anticomplementary ac-
tivity, however, has been reported with certain in vitro
reactants [35] and sera [43], and it is clear that assays
which utilize unheated test sera are at an advantage in
this regard. Thus, Zubler et al [42] recently modified
the ICIqBA so that EDTA is used in place of heat
inactivation with an apparent increase in the preva-
lence of detection of IC in lupus sera.
The specificity of the assays must also be estab-
lished. In particular, Clq is known to bind endotoxin
[44] and polyanionic substances [45, 46] and, since
neither the fluid phase of ICIqBA nor the MCT have
IgG-specific end-points, such substances could pro-
duce false positive results. In this study, the in vitro
addition of endotoxin, heparin, or DNA to normal
human serum (NHS) produced anticomplementary
activity in the MCT. The IC1qBA was affected by
heparin, and to a lesser extent DNA, but not by
endotoxin. The IC I qBA detects macromolecular Cl q
reactants which are insoluble in 2.6% polyethylene
glycol (PEG). Endotoxin and DNA are PEG-soluble
[42], while heparin (mol wt, 6,000 to 20,000) is pre-
sumably bound to serum proteins to form PEG-in-
soluble complexes. The effects of suboptimal han-
dling and storage conditions of test sera were also
evaluated. The MCT was particularly susceptible to
such factors, and NHS rapidly became anti-
complementary unless stored at —70°C. The IRCA
Table 6. Serum complement (C) data on patients in prospective
study
Serum C levelsa
Prevalence of positivity in
immune corn plex assays, %
IRCA ICIqBA MCI
C3 low (N = 40)
C3 normal (N = 45)
45 28 26
20 22 18
C4 low (N = 27)
C4normal(N=58)
59 30 35
19 22 16
C3PA low (N = 21)
C3PAnormal(N=64)
52 33 30
25 22 19
a Normal range for C3 is 1104 to l373sg/ml; C4, 456 to 745
/2g/ml; and C3PA, 153 to 226tg/ml.b Abbreviations used are: IRCA, the Raji radioimmune assay;
ICIqBA, the radiolabeled Clq-binding assay; MCI, the micro-
complement consumption test.
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was little affected by these conditions and was not
influenced by heparin, DNA, or endotoxin. There is,
however, some evidence that serum antilymphocyte
antibodies can influence the IRCA. Warm, reactive
IgG-type serum antilymphocyte antibodies have
been identified in SLE [47], and it is likely that these
contribute to IRCA positivity in some lupus sera.
The above considerations are important in the in-
terpretation of data generated by IC assays, and
wherever possible the data should be corroborated by
independent serologic and tissue (IF) studies. The
specificity of the MCT is particularly questionable,
and this assay is best regarded as a screening test. In
our hands, the lClqBA is less sensitive than the
IRCA, and we detected IC in only 8 of 23 patients
with SLE. This may be due in part to the deleterious
effects of preliminary heat-inactivation of test sera
[42]; and in using EDTA-treated sera in the IgG-
specific solid phase Clq assay [17], we detected IC in
six of nine patients with SLE (Tung et al, submitted
for publication). The ICIqBA detected large
amounts of IC in some IRCA-negative patients (par-
ticularly those with GN and systemic diseases other
than SLE). The reactivities of the two assays are
different: the IRCA-detects IC which have fixed C3
in vivo, and the IClqBa detects IC which can fix addi-
tional Clq in vitro. These different reactivities can be
exploited by using the assays in combination.
In this study, and in others [15, 17, 21, 22, 36, 41,
42], lCs were detected most frequently in SLE. Sim-
ilarly, circulating ICs were detected more frequently
in GN associated with other systemic diseases than in
primary GN, suggesting the presence of a heavy IC
load in these conditions. Quantitative data support
this concept. ICs were detected with one or more of
the assays in 39% of patients with primary GN and
were present more frequently in acute GN than in
chronic GN (MGN, MPGN, etc.). Again, this may
reflect quantitative differences in the amounts of cir-
culating IC, but it is also possible that IC are present
in the circulation only intermittently or with chang-
ing antigen:antibody ratios in these conditions and
that the timing of IC determinations is critical. In
experimental serum sickness, it is clear that glomeru-
lar bound ICs are in dynamic equilibrium with antigen
and antibody from the circulation [I], and that once
established, the disease could be maintained by gb-
merular deposition of noncomplexed antigen or anti-
body. Finally, the apparent low levels of circulating
IC in primary GN may presuppose qualitative differ-
ences in the composition or handling of more or less
physiologic amounts of IC in these patients. That is,
immune complex-induced renal disease may be in-
fluenced not only by the load of immune complex
material but also by the subsequent processing of
potentially phiogogenic materials by the host.
Our inability to detect circulating IC in all patients
with presumed IC-mediated GN is shared by others.
Thus, Johnson et al [41] described serum anti-
complementary activity in 19 of 51 (37%) patients
with GN; StCihlinger et al [36], using the macrophage
uptake assay, detected circulating IC in 29 of 60
(48%) patients with GN; Rossen et al [48], using the
IC1qBA, detected circulating IC in 18 of 100 (18%)
patients with GN; Gluckman et al [49], using the
lymphocyte EAC rosette test, reported inhibition in
32 of 67 (48%) patients with GN; and Sobel et al [37],
using the Clq deviation test, detected circulating IC
in approximately 40% of patients with GN. Some of
the current difficulties may be resolved as more sensi-
tive and specific IC assays become available. In the
meantime, the assays are perhaps more valuable as
research probes for antigen identification than clin-
ically useful serologic determinants of ICON.
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